Amplion Blog ArriVent Biopharma: Company Profile

Overview ArriVent Biopharma (https://arrivent.com/) is a clinical-stage biotechnology company based in Newtown Square, PA with 42 employees (Sep, 2023) developing targeted oncology therapies. The company was founded in 2021 with a $150 million Series A financing. Pipeline and Technology ArriVent's lead asset is furmonertinib, an epidermal growth factor receptor (EGFR) inhibitor, licensed from Allist Pharmaceuticals. [...]The post ArriVent Biopharma: Company Profile appeared first on Amplion.